BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Spearman CW, Dusheiko GM, Hellard M, Sonderup M. Hepatitis C. Lancet. 2019;394:1451-1466. [PMID: 31 DOI: 10.1016/s0140-6736(19)32320-7] [Cited by in Crossref: 191] [Cited by in F6Publishing: 201] [Article Influence: 4.1] [Reference Citation Analysis]
Number Citing Articles
1 Nishikawa K, Kimura M, Imamura J, Kimura K. Prevalence of hepatitis C virus infection among men who have sex with men with human immunodeficiency virus-1 infection between 2010 and 2020 in Japan: A single-center retrospective cohort study. J Infect Chemother 2023;29:263-8. [PMID: 36585274 DOI: 10.1016/j.jiac.2022.11.009] [Reference Citation Analysis]
2 Pinchera B, Moriello NS, Buonomo AR, Zappulo E, Viceconte G, Villari R, Gentile I. Microbiota and hepatitis C virus in the era of direct-acting antiviral agents. Microb Pathog 2023;175:105968. [PMID: 36626945 DOI: 10.1016/j.micpath.2023.105968] [Reference Citation Analysis]
3 Cheng PN, Sun HY, Feng IC, Chiu YC, Wang ST, Tan DC, Chiu HC, Chien SC, Young KC. Interdependence of glycemic and lipid modulation in cured chronic hepatitis C patients by direct-acting antiviral agents. J Microbiol Immunol Infect 2023;56:20-30. [PMID: 35842406 DOI: 10.1016/j.jmii.2022.06.004] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Sepúlveda-Crespo D, Treviño-Nakoura A, Bellon JM, Jiménez-Sousa MA, Ryan P, Martínez I, Fernández-Rodríguez A, Resino S. Diagnostic Performance of the HCV Core Antigen Test To Identify Hepatitis C in HIV-Infected Patients: a Systematic Review and Meta-Analysis. J Clin Microbiol 2023;61:e0133122. [PMID: 36537787 DOI: 10.1128/jcm.01331-22] [Reference Citation Analysis]
5 Pratedrat P, Nilyanimit P, Wasitthankasem R, Posuwan N, Auphimai C, Hansoongnern P, Pimsing N, Ngamnimit S, Thongmai C, Phaengkha W, Wanlapakorn N, Vongpunsawad S, Poovorawan Y. Qualitative hepatitis C virus RNA assay identifies active infection with sufficient viral load for treatment among Phetchabun residents in Thailand. PLoS One 2023;18:e0268728. [PMID: 36656832 DOI: 10.1371/journal.pone.0268728] [Reference Citation Analysis]
6 Huang H, Mehta A, Kalmanovich J, Anand A, Bejarano MC, Garg T, Khan N, Tonpouwo GK, Shkodina AD, Bardhan M. Immunological and inflammatory effects of infectious diseases in circadian rhythm disruption and future therapeutic directions. Mol Biol Rep 2023;:1-15. [PMID: 36656437 DOI: 10.1007/s11033-023-08276-w] [Reference Citation Analysis]
7 Khalili M, Kim NJ, Tsoh JY, Walsh JME, Elizabeth Goldman L, Park H, Lau I, Wong C, Gildengorin G, Nguyen TT. Efficacy of a Primary Care-Based Mobile Application to Increase Hepatitis C Screening Among Asian Americans: A Secondary Analysis of a Randomized Clinical Trial. Open Forum Infect Dis 2023;10:ofad002. [PMID: 36726551 DOI: 10.1093/ofid/ofad002] [Reference Citation Analysis]
8 Arici N, Kansak N, Adaleti R, Aksaray S, Ankarali H. YERLİ VE YABANCI KRONİK HEPATİT C HASTALARINDA HCV GENOTİPLERİNİN DAĞILIMI: 6 YILLIK DEĞERLENDİRME. ANKEM Derg 2022. [DOI: 10.54962/ankemderg.1216808] [Reference Citation Analysis]
9 Kozuka R, Tamori A, Enomoto M, Muto-Yukawa Y, Odagiri N, Kotani K, Motoyama H, Kawamura E, Hagihara A, Fujii H, Uchida-Kobayashi S, Kawada N. Risk factors for liver-related and non-liver-related mortality following a sustained virological response after direct-acting antiviral treatment for hepatitis C virus infection in a real-world cohort. J Viral Hepat 2022. [PMID: 36583600 DOI: 10.1111/jvh.13795] [Reference Citation Analysis]
10 Gao J, Wang Q, Tang Y, Zhai J, Hu W, Zheng C. When ferroptosis meets pathogenic infections. Trends in Microbiology 2022. [DOI: 10.1016/j.tim.2022.11.006] [Reference Citation Analysis]
11 Huarez B, Hernández-Vásquez A, Azañedo D, Vargas-Fernández R, Comandé D, Agüero-Palacios Y. Prevalence of hepatitis C virus infection in patients with end-stage renal disease in Latin America and the Caribbean: a systematic review and meta-analysis. Arch Virol 2022;167:2653-64. [PMID: 36195804 DOI: 10.1007/s00705-022-05604-6] [Reference Citation Analysis]
12 Nkwocha CL, Carter PS, Blair S, Blackwell JM, Fasanmi EO. Understanding the effect of direct-acting antiviral therapy on weight in patients with chronic hepatitis C. Antivir Ther 2022;27:13596535221115253. [PMID: 36495070 DOI: 10.1177/13596535221115253] [Reference Citation Analysis]
13 Carty PG, Teljeur C, De Gascun CF, Gillespie P, Harrington P, McCormick A, O'Neill M, Smith SM, Ryan M. Another Step Toward Hepatitis C Elimination: An Economic Evaluation of an Irish National Birth Cohort Testing Program. Value Health 2022;25:1947-57. [PMID: 35778325 DOI: 10.1016/j.jval.2022.05.010] [Reference Citation Analysis]
14 Radmanić L, Korać P, Gorenec L, Šimičić P, Bodulić K, Vince A, Lepej SŽ. Distinct Expression Patterns of Genes Coding for Biological Response Modifiers Involved in Inflammatory Responses and Development of Fibrosis in Chronic Hepatitis C: Upregulation of SMAD-6 and MMP-8 and Downregulation of CAV-1, CTGF, CEBPB, PLG, TIMP-3, MMP-1, ITGA-1, ITGA-2 and LOX. Medicina (Kaunas) 2022;58. [PMID: 36556936 DOI: 10.3390/medicina58121734] [Reference Citation Analysis]
15 Ljungquist O, Olinder J, Tverring J, Kjölvmark C, Torisson G. Agreement and reliability of transient elastography in patients with chronic hepatitis C - a cross-sectional test-retest study.. [DOI: 10.21203/rs.3.rs-2232604/v1] [Reference Citation Analysis]
16 Moustafa S, Kassela K, Bampali M, Dovrolis N, Kakkanas A, Beloukas A, Mavromara P, Karakasiliotis I. Hepatitis C Core Protein Induces a Genotype-Specific Susceptibility of Hepatocytes to TNF-Induced Death In Vitro and In Vivo. Viruses 2022;14. [PMID: 36423130 DOI: 10.3390/v14112521] [Reference Citation Analysis]
17 Suslov A, Heim MH, Wieland S. Studying Hepatitis Virus-Host Interactions in Patient Liver Biopsies. Viruses 2022;14. [PMID: 36366588 DOI: 10.3390/v14112490] [Reference Citation Analysis]
18 Precious DN. Hepatitis B and C Co-Infection among HIV-Positive Patients Attending Art at General Hospital Kaltungo, Gombe State, Nigeria. J Immuno Allerg 2022. [DOI: 10.37191/mapsci-2582-6549-3(2)-038] [Reference Citation Analysis]
19 Guerra-Veloz MF, Han K, Oakes K, Robertson D, Mohamed A, Cannon M, Barnabas A, Shah S, Halford R, Dusheiko G, Agarwal K. Results of a Model of Delivering Hepatitis C Care in a Homeless Metropolitan Population in England. Am J Gastroenterol 2022. [PMID: 36191276 DOI: 10.14309/ajg.0000000000002041] [Reference Citation Analysis]
20 Reynolds L, Franco R, Prados M, Rodgers JB, Hand DT, Walter LA. Hepatitis C active viremia over time in an ED-based testing programme: Impact, disparities and surveillance tool. J Viral Hepat 2022;29:1026-34. [PMID: 36062383 DOI: 10.1111/jvh.13744] [Reference Citation Analysis]
21 Calvaruso V, Celsa C, D'Ambrosio R, Simone F, Petta S, Cacciola I, Enea M, Battaglia S, Pandolfo A, Licata M, Degasperi E, Cabibbo G, Di Marco L, Pennisi G, Borghi M, Di Martino V, Filomia R, Abdel-Hadi Y, Crapanzano L, Raimondo G, Lampertico P, Craxì A, Cammà C, Di Marco V. RESIST-HCV Criteria to Monitor Progression of Low-Risk Esophageal Varices in Patients With Compensated Cirrhosis After HCV Eradication: The SIMPLE Study: SIMPLE: Scoring Index to Monitor Progression of Low-risk Esophageal varices. Am J Gastroenterol 2022;117:1816-24. [PMID: 35973181 DOI: 10.14309/ajg.0000000000001878] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Sepúlveda-Crespo D, Treviño-Nakoura A, Bellon JM, Ardizone Jiménez B, Jiménez-Sousa MA, Fernández-Rodríguez A, Martínez I, Resino S. Meta-analysis: diagnostic accuracy of hepatitis C core antigen detection during therapy with direct-acting antivirals. Aliment Pharmacol Ther 2022;56:1224-34. [PMID: 36031747 DOI: 10.1111/apt.17198] [Reference Citation Analysis]
23 Fidan Ö. Investigation of Antiviral Potential of Food Carotenoids and Apocarotenoids against RNA-dependent RNA Polymerase of Hepatitis C Virus. Bitlis Eren Üniversitesi Fen Bilimleri Dergisi 2022;11:931-942. [DOI: 10.17798/bitlisfen.1161170] [Reference Citation Analysis]
24 Bao K, Chen J, Liu R, Xiang Y, Gao W. Prevalence of HCV Infection Among Hemodialysis Patients in Lanzhou of Northwestern China. Infect Drug Resist 2022;15:5609-17. [PMID: 36172622 DOI: 10.2147/IDR.S378600] [Reference Citation Analysis]
25 Ferri LP, Junqueira PDS, de Almeida MMS, Oliveira MG, de Oliveira BR, Diniz e Silva BV, Magalhães LS, Villar LM, Caetano KAA, Souza MM, Carneiro MADS, Martins RMB, Teles SA. Viral Hepatitis A, B and C in a Group of Transgender Women in Central Brazil. TropicalMed 2022;7:269. [DOI: 10.3390/tropicalmed7100269] [Reference Citation Analysis]
26 Kim S, Oh Y, Ko D, Sung H, Oh H, Hwang S. Nanoparticle-Based Visual Detection of Amplified DNA for Diagnosis of Hepatitis C Virus. Biosensors 2022;12:744. [DOI: 10.3390/bios12090744] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
27 Ramos-Rincon JM, Pinargote-Celorio H, de Mendoza C, Ramos-Belinchón C, Barreiro P, Gómez-Gallego F, Corral O, Soriano V. Hepatitis C hospitalizations in Spain and impact of new curative antiviral therapies. J Viral Hepat 2022;29:777-84. [PMID: 35643914 DOI: 10.1111/jvh.13708] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
28 Huang CH, Fan JH, Jeng WJ, Chang ST, Yang CK, Teng W, Wu TH, Hsieh YC, Chen WT, Chen YC, Sheen IS, Lin YC, Lin CY. Innate-like bystander-activated CD38(+) HLA-DR(+) CD8(+) T cells play a pathogenic role in patients with chronic hepatitis C. Hepatology 2022;76:803-18. [PMID: 35060158 DOI: 10.1002/hep.32349] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
29 Liu H, Yang XL, Dong ZR, Chen ZQ, Hong JG, Wang DX, Li T. Clinical benefits of direct-acting antivirals therapy in hepatitis C virus patients with hepatocellular carcinoma: A systematic review and meta-analysis. J Gastroenterol Hepatol 2022;37:1654-65. [PMID: 35722709 DOI: 10.1111/jgh.15915] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
30 Raja SS, Edwards S, Stewart J, Huynh D. Missed opportunities for hepatitis C treatment at a tertiary care hospital in South Australia. World J Hepatol 2022; 14(8): 1576-1583 [DOI: 10.4254/wjh.v14.i8.1576] [Reference Citation Analysis]
31 Jones AT, Briones C, Tran T, Moreno-Walton L, Kissinger PJ. Closing the hepatitis C treatment gap: United States strategies to improve retention in care. J Viral Hepat 2022;29:588-95. [PMID: 35545901 DOI: 10.1111/jvh.13685] [Reference Citation Analysis]
32 Benade M, Rosen S, Antoniak S, Chasela C, Stopolianska Y, Barnard T, Gandhi MM, Ivanchuk I, Tretiakov V, Dible J, Minior T, Chew KW, van der Horst C, Tsenilova Z, Sanne I. Impact of direct-acting antiviral treatment of hepatitis C on the quality of life of adults in Ukraine. BMC Infect Dis 2022;22:650. [PMID: 35896987 DOI: 10.1186/s12879-022-07615-9] [Reference Citation Analysis]
33 Anwar MI, Li N, Zhou Q, Chen M, Hu C, Wu T, Chen H, Li YP, Zhou Y. PPP2R5D promotes hepatitis C virus infection by binding to viral NS5B and enhancing viral RNA replication. Virol J 2022;19:118. [PMID: 35836293 DOI: 10.1186/s12985-022-01848-5] [Reference Citation Analysis]
34 Zhou Z, Zhang J, Zhou E, Ren C, Wang J, Wang Y. Small molecule NS5B RdRp non-nucleoside inhibitors for the treatment of HCV infection: A medicinal chemistry perspective. Eur J Med Chem 2022;240:114595. [PMID: 35868125 DOI: 10.1016/j.ejmech.2022.114595] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
35 Imbeth-acosta P, Leal-martínez V, Ramos-clason E, Pájaro-galvis N, Martínez-ávila MC, Almanza-hurtado A, Rodríguez-yanez T, Bermudez-montero J, Vergara-serpa O, Abuabara-franco E, Raad-sarabia M, Villar-gonzález EP, Tatis-geney SI, Collazos-torres LA, Rico-fontalvo J, Daza-arnedo R, Pérez-calvo C, Alvarado-castell H, López Acuña GH. Prevalence of Chronic Infection by Hepatitis C Virus in Asymptomatic Population With Risk Factors in Cartagena, Colombia. Front Med 2022;9:814622. [DOI: 10.3389/fmed.2022.814622] [Reference Citation Analysis]
36 Kuwano A, Yada M, Nagasawa S, Tanaka K, Morita Y, Masumoto A, Motomura K. Hepatitis C virus eradication ameliorates the prognosis of advanced hepatocellular carcinoma treated with sorafenib. J Viral Hepat 2022;29:543-50. [PMID: 35499194 DOI: 10.1111/jvh.13681] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
37 Lockart I, Yeo MGH, Hajarizadeh B, Dore GJ, Danta M. HCC incidence after hepatitis C cure among patients with advanced fibrosis or cirrhosis: A meta-analysis. Hepatology 2022;76:139-54. [PMID: 35030279 DOI: 10.1002/hep.32341] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
38 Zhou S, Yao Z. Roles of Infection in Psoriasis. IJMS 2022;23:6955. [DOI: 10.3390/ijms23136955] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
39 Chuaypen N, Siripongsakun S, Hiranrat P, Tanpowpong N, Avihingsanon A, Tangkijvanich P. Improvement of liver fibrosis, but not steatosis, after HCV eradication as assessment by MR-based imaging: Role of metabolic derangement and host genetic variants. PLoS ONE 2022;17:e0269641. [DOI: 10.1371/journal.pone.0269641] [Reference Citation Analysis]
40 Feng Z, Zhang J, Tan W, Wang C, Chen Q, Shen C, Fan H, Zhang Y, Huang P, Yue M. Efficacy and Safety of Direct-Acting Antivirals in Kidney Transplantation From HCV-Viremic Donors to Negative Recipients: A Meta-Analysis. Front Med (Lausanne) 2022;9:802686. [PMID: 35665327 DOI: 10.3389/fmed.2022.802686] [Reference Citation Analysis]
41 Ramos-Rincon JM, Pinargote-Celorio H, de Mendoza C, Ramos-Belinchón C, Barreiro P, Treviño A, Corral O, Soriano V. Liver cancer and hepatic decompensation events in patients hospitalized with viral hepatitis in Spain. Hepatol Int 2022. [PMID: 35666390 DOI: 10.1007/s12072-022-10365-0] [Reference Citation Analysis]
42 Cherepnin MA, Tsukanov VV, Savchenko AA, Vasyutin AV, Kasparov EV, Tonkikh JL, Borisov AG. Comparison of clinical and laboratory characteristics and frequency of liver fibrosis in patients with chronic viral hepatitis C of the first and third genotypes. Medicinskij sovet 2022. [DOI: 10.21518/2079-701x-2022-16-7-98-103] [Reference Citation Analysis]
43 Liu Y, Su J, Wang X, Xu H, Wang H, Kang R, Zheng L, Wang Y, Liu C, Jing Y, Zhang S. Knowledge and self-reported testing behaviours of hepatitis C in the general population in China: an online cross-sectional survey (Preprint).. [DOI: 10.2196/preprints.39472] [Reference Citation Analysis]
44 Pratedrat P, Nilyanimit P, Wasitthankasem R, Posuwan N, Auphimai C, Hansoongnern P, Pimsing N, Ngamnimit S, Thongmai C, Phaengkha W, Wanlapakorn N, Vongpunsawad S, Poovorawan Y. Qualitative hepatitis C virus RNA assay identifies active infection with sufficient viral load for treatment among Phetchabun residents in Thailand.. [DOI: 10.1101/2022.05.09.22274856] [Reference Citation Analysis]
45 Fujii H, Kimura H, Hasebe C, Akahane T, Satou T, Kusakabe A, Kojima Y, Kondo M, Marusawa H, Kobashi H, Tsuji K, Ogawa C, Uchida Y, Joko K, Mitsuda A, Kurosaki M, Izumi N. Real‐world long‐term analysis of daclatasvir plus asunaprevir in patients with hepatitis C virus infection. JGH Open. [DOI: 10.1002/jgh3.12749] [Reference Citation Analysis]
46 Politi J, Guerras JM, Donat M, Belza MJ, Ronda E, Barrio G, Regidor E. Favorable impact in hepatitis C-related mortality following free access to direct-acting antivirals in Spain. Hepatology 2022;75:1247-56. [PMID: 34773281 DOI: 10.1002/hep.32237] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
47 Di Stasio D, Lucchese A, Romano A, Elio Adinolfi L, Serpico R, Marrone A. The clinical impact of direct-acting antiviral treatment on patients affected by hepatitis C virus-related oral lichen planus: a cohort study. Clin Oral Investig 2022. [PMID: 35477818 DOI: 10.1007/s00784-022-04507-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
48 Ghany MG, Liang TJ. Acute viral hepatitis. In: Wang TC, Camilleri M, Lebwohl B, Lok AS, Sandborn WJ, Wang KK, Wu GD, editors. Yamada's Textbook of Gastroenterology. Wiley; 2022. pp. 1804-40. [DOI: 10.1002/9781119600206.ch86] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
49 Chang ML, Cheng JS, Chuang YH, Pao LH, Wu TS, Chen SC, Chang MY, Chien RN. Evolution of Cryoglobulinemia in Direct-Acting Antiviral-Treated Asian Hepatitis C Patients With Sustained Virological Responses: A 4-Year Prospective Cohort Study. Front Immunol 2022;13:823160. [PMID: 35371039 DOI: 10.3389/fimmu.2022.823160] [Reference Citation Analysis]
50 Devi P, Punga T, Bergqvist A. Activation of the Ca2+/NFAT Pathway by Assembly of Hepatitis C Virus Core Protein into Nucleocapsid-like Particles. Viruses 2022;14:761. [DOI: 10.3390/v14040761] [Reference Citation Analysis]
51 Nagra N, Kozarek RA, Burman BE. Therapeutic Advances in Viral Hepatitis A-E. Adv Ther 2022;39:1524-52. [PMID: 35220557 DOI: 10.1007/s12325-022-02070-z] [Reference Citation Analysis]
52 Fartushna OY, Prokopiv MM, Krylova VY, Rohoza SV, Palahuta HV, Hnepa YY, Fartushnyi YM. ASEPTIC MENINGITIS AS AN EXTRAHEPATIC MANIFESTATION OF HEPATITIS C: A CLINICAL CASE PRESENTATIONIN A WHITE YOUNG FEMALE EUROPEAN ADULT. Wiad Lek 2022;75:1043-1046. [DOI: 10.36740/wlek20220420123] [Reference Citation Analysis]
53 Diepolder H. Hepatitis A bis E. CME 2022;19:53-65. [DOI: 10.1007/s11298-022-2344-8] [Reference Citation Analysis]
54 Lyu H, Tang H, Liang Y, Huang S, Wang Y, Huang W, Zhou Y. Alcohol Consumption and Risk of Liver Fibrosis in People Living With HIV: A Systematic Review and Meta-Analysis. Front Immunol 2022;13:841314. [DOI: 10.3389/fimmu.2022.841314] [Reference Citation Analysis]
55 Reinecke B, Frericks N, Lauber C, Dinkelborg K, Matthaei A, Vondran FWR, Behrendt P, Haid S, Brown RJP, Pietschmann T. The Human Liver-Expressed Lectin CD302 Restricts Hepatitis C Virus Infection. J Virol 2022;:e0199521. [PMID: 35297672 DOI: 10.1128/jvi.01995-21] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
56 Dröse S, Øvrehus ALH, Holm DK, Madsen LW, Mössner BK, Søholm J, Hansen JF, Røge BT, Christensen PB. A multi-level intervention to eliminate hepatitis C from the Region of Southern Denmark: the C-Free-South project. BMC Infect Dis 2022;22:202. [PMID: 35232372 DOI: 10.1186/s12879-022-07196-7] [Reference Citation Analysis]
57 Winter RJ, Holmes JA, Papaluca TJ, Thompson AJ. The Importance of Prisons in Achieving Hepatitis C Elimination: Insights from the Australian Experience. Viruses 2022;14:497. [DOI: 10.3390/v14030497] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
58 Taniki N, Nakamoto N, Chu PS, Ichikawa M, Teratani T, Kanai T. Th17 cells in the liver: balancing autoimmunity and pathogen defense. Semin Immunopathol 2022. [PMID: 35211777 DOI: 10.1007/s00281-022-00917-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
59 Wang H, Zhang Y, Zhou J, Li M, Chen Y, Liu Y, Liu H, Ding P, Liang C, Zhu X, Zhang Y, Xin C, Zhang G, Wang A. Rapid Visual Detection of Hepatitis C Virus Using Reverse Transcription Recombinase-Aided Amplification–Lateral Flow Dipstick. Front Cell Infect Microbiol 2022;12:816238. [DOI: 10.3389/fcimb.2022.816238] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
60 Bajdechi G, Voiosu RM. Modern Treatment of Hepatitis C Infection. Internal Medicine 2022;19:37-52. [DOI: 10.2478/inmed-2022-0206] [Reference Citation Analysis]
61 Kouroumalis E, Voumvouraki A. Hepatitis C virus: A critical approach to who really needs treatment. World J Hepatol 2022; 14(1): 1-44 [DOI: 10.4254/wjh.v14.i1.1] [Reference Citation Analysis]
62 Liu C, Shih YF, Liu CJ. Immunopathogenesis of Acute Flare of Chronic Hepatitis B: With Emphasis on the Role of Cytokines and Chemokines. Int J Mol Sci 2022;23:1407. [PMID: 35163330 DOI: 10.3390/ijms23031407] [Reference Citation Analysis]
63 de Brito RJVC, da Silva LF, Santos MB, de Moura PMMF, de Souza CDF, do Carmo RF. A time series analysis of detection and mortality of hepatitis C in Brazil, 2008–2018. BMC Infect Dis 2022;22. [DOI: 10.1186/s12879-022-07063-5] [Reference Citation Analysis]
64 Chuaypen N, Khlaiphuengsin A, Prasoppokakorn T, Susantitaphong P, Prasithsirikul W, Avihingsanon A, Tangkijvanich P, Praditpornsilpa K. Prevalence and genotype distribution of hepatitis C virus within hemodialysis units in Thailand: role of HCV core antigen in the assessment of viremia. BMC Infect Dis 2022;22. [DOI: 10.1186/s12879-022-07074-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
65 Krag A, Roskams T, Pinzani M, Mueller S. Diagnostic challenges in patients with alcohol-related liver disease. Z Gastroenterol 2022;60:45-57. [PMID: 35042253 DOI: 10.1055/a-1713-4372] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
66 Tunney R, Prince M, Athwal V. Chronic Hepatitis C. In Clinical Practice 2022. [DOI: 10.1007/978-3-031-10012-3_9] [Reference Citation Analysis]
67 Von den Hoff DW, Berden FAC, Drenth JPH, Schellekens AFA; HepNed, NISPA. Implementation of a decentralized hepatitis C care pathway for people who use drugs in Dutch addiction care. Study protocol for the Hepatitis C: chain of addiction care (CAC) project. Addict Sci Clin Pract 2022;17:67. [PMID: 36451175 DOI: 10.1186/s13722-022-00350-1] [Reference Citation Analysis]
68 Blumberg EA. Using Hepatitis C-Positive Donors and Other High-Risk Donors. Contemporary Lung Transplantation 2022. [DOI: 10.1007/978-3-319-20788-9_20-1] [Reference Citation Analysis]
69 Qian X, Qi Z. Entry Inhibitors of Hepatitis C Virus. Advances in Experimental Medicine and Biology 2022. [DOI: 10.1007/978-981-16-8702-0_13] [Reference Citation Analysis]
70 . Viszeralchirurgie. FAP Allgemein- und Viszeralchirurgie 2022. [DOI: 10.1016/b978-3-437-23244-2.00005-7] [Reference Citation Analysis]
71 Talebi A, Kargar M. Hepatoprotective effects of metformin in hepatitis C virus-infected adolescents with beta thalassaemia major. Int J Clin Pract 2021;75:e14951. [PMID: 34965654 DOI: 10.1111/ijcp.14951] [Reference Citation Analysis]
72 Chen M, Xu Y, Li N, Yin P, Zhou Q, Feng S, Wu T, Wei L, Wang H, Fu Y, Li Y. Development of full-length cell-culture infectious clone and subgenomic replicon for a genotype 3a isolate of hepatitis C virus. Journal of General Virology 2021;102. [DOI: 10.1099/jgv.0.001704] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
73 Goodman S, Zahn M, Bruckner T, Boden-Albala B, Lakon CM. Measuring Hazards of Undetectable Viral Load among Hepatitis C Antibody Positive Residents of a Large Southern California County. Health Serv Res Manag Epidemiol 2021;8:23333928211066181. [PMID: 34926722 DOI: 10.1177/23333928211066181] [Reference Citation Analysis]
74 Desombere I, Van Houtte F, Farhoudi A, Verhoye L, Buysschaert C, Gijbels Y, Couvent S, Swinnen W, Van Vlierberghe H, Elewaut A, Magri A, Stamataki Z, Meuleman P, Mckeating JA, Leroux-roels G. A Role for B Cells to Transmit Hepatitis C Virus Infection. Front Immunol 2021;12. [DOI: 10.3389/fimmu.2021.775098] [Reference Citation Analysis]
75 Gu W, Hortlik H, Erasmus HP, Schaaf L, Zeleke Y, Uschner FE, Ferstl P, Schulz M, Peiffer KH, Queck A, Sauerbruch T, Brol MJ, Rohde G, Sanchez C, Moreau R, Arroyo V, Zeuzem S, Welsch C, Trebicka J. Trends and the course of liver cirrhosis and its complications in Germany: Nationwide population-based study (2005 to 2018). Lancet Reg Health Eur 2022;12:100240. [PMID: 34901909 DOI: 10.1016/j.lanepe.2021.100240] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 4.5] [Reference Citation Analysis]
76 Tabata K, Prasad V, Paul D, Lee JY, Pham MT, Twu WI, Neufeldt CJ, Cortese M, Cerikan B, Stahl Y, Joecks S, Tran CS, Lüchtenborg C, V'kovski P, Hörmann K, Müller AC, Zitzmann C, Haselmann U, Beneke J, Kaderali L, Erfle H, Thiel V, Lohmann V, Superti-Furga G, Brügger B, Bartenschlager R. Convergent use of phosphatidic acid for hepatitis C virus and SARS-CoV-2 replication organelle formation. Nat Commun 2021;12:7276. [PMID: 34907161 DOI: 10.1038/s41467-021-27511-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 5.5] [Reference Citation Analysis]
77 Virseda-Berdices A, Brochado-Kith O, Díez C, Hontañon V, Berenguer J, González-García J, Rojo D, Fernández-Rodríguez A, Ibañez-Samaniego L, Llop-Herrera E, Olveira A, Perez-Latorre L, Barbas C, Rava M, Resino S, Jiménez-Sousa MA. Blood microbiome is associated with changes in portal hypertension after successful direct-acting antiviral therapy in patients with HCV-related cirrhosis. J Antimicrob Chemother 2021:dkab444. [PMID: 34888660 DOI: 10.1093/jac/dkab444] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
78 Paisi M, Crombag N, Burns L, Bogaerts A, Withers L, Bates L, Crowley D, Witton R, Shawe J. Barriers and facilitators to hepatitis C screening and treatment for people with lived experience of homelessness: A mixed-methods systematic review. Health Expect 2021. [PMID: 34862710 DOI: 10.1111/hex.13400] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
79 Gao Y, Nepal N, Jin SZ. Toll-like receptors and hepatitis C virus infection. Hepatobiliary Pancreat Dis Int 2021;20:521-9. [PMID: 34419367 DOI: 10.1016/j.hbpd.2021.07.011] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
80 Martini F, Champagne E. The Contribution of Human Herpes Viruses to γδ T Cell Mobilisation in Co-Infections. Viruses 2021;13:2372. [PMID: 34960641 DOI: 10.3390/v13122372] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
81 Gebert LFR, Law M, MacRae IJ. A structured RNA motif locks Argonaute2:miR-122 onto the 5' end of the HCV genome. Nat Commun 2021;12:6836. [PMID: 34824224 DOI: 10.1038/s41467-021-27177-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
82 Fu K, Wang C, Ma C, Zhou H, Li Y. The Potential Application of Chinese Medicine in Liver Diseases: A New Opportunity. Front Pharmacol 2021;12:771459. [PMID: 34803712 DOI: 10.3389/fphar.2021.771459] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
83 Delgado Martínez C, Gómez-Rubio M, Gómez-Domínguez C. Is hepatitis C direct-acting antiviral therapy a risk factor for the development and recurrence of hepatocellular carcinoma? Narrative literature review and clinical practice recommendations. Ann Hepatol 2021;21:100225. [PMID: 32687878 DOI: 10.1016/j.aohep.2020.05.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
84 Kudrina I, Puzhko S, Filion KB, Gore G, Paraskevopoulos E, Windle S, Martel MO, Eisenberg MJ. Effectiveness of interventions for prevention of common infections in people who use opioids: a protocol for a systematic review of systematic reviews. Syst Rev 2021;10:298. [PMID: 34782008 DOI: 10.1186/s13643-021-01852-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
85 Ouoba S, Ouedraogo JCRP, Lingani M, E B, Hussain MRA, Ko K, Nagashima S, Sugiyama A, Akita T, Tinto H, Tanaka J. Epidemiologic profile of hepatitis C virus infection and genotype distribution in Burkina Faso: a systematic review with meta-analysis. BMC Infect Dis 2021;21:1126. [PMID: 34724902 DOI: 10.1186/s12879-021-06817-x] [Reference Citation Analysis]
86 Lee H, Chien RN, Pao LH, Kuo CJ, Huang PH, Chang ML. Decoupled Glucose and Lipid Metabolic Recovery after Viral Clearance in Direct-Acting Antiviral-Treated HCV Patients: A 3-Year Prospective Cohort Study. Cells 2021;10:2934. [PMID: 34831156 DOI: 10.3390/cells10112934] [Reference Citation Analysis]
87 Shenge JA, Osiowy C. Rapid Diagnostics for Hepatitis B and C Viruses in Low- and Middle-Income Countries. Front Virol 2021;1:742722. [DOI: 10.3389/fviro.2021.742722] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
88 Ginès P, Krag A, Abraldes JG, Solà E, Fabrellas N, Kamath PS. Liver cirrhosis. Lancet 2021;398:1359-76. [PMID: 34543610 DOI: 10.1016/S0140-6736(21)01374-X] [Cited by in Crossref: 84] [Cited by in F6Publishing: 99] [Article Influence: 42.0] [Reference Citation Analysis]
89 Shoukry NH, Walker CM. T cell responses during HBV and HCV infections: similar but not quite the same? Curr Opin Virol 2021;51:80-6. [PMID: 34619514 DOI: 10.1016/j.coviro.2021.08.011] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
90 Erice A, Varillas-Delgado D, Caballero C. Prevalence and characteristics of hepatitis C virus infection detected by extended screening of working-age adults in Madrid (Spain). J Viral Hepat 2021;28:1496-9. [PMID: 34224188 DOI: 10.1111/jvh.13564] [Reference Citation Analysis]
91 Barili V, Vecchi A, Rossi M, Montali I, Tiezzi C, Penna A, Laccabue D, Missale G, Fisicaro P, Boni C. Unraveling the Multifaceted Nature of CD8 T Cell Exhaustion Provides the Molecular Basis for Therapeutic T Cell Reconstitution in Chronic Hepatitis B and C. Cells 2021;10:2563. [PMID: 34685543 DOI: 10.3390/cells10102563] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
92 Chang ML, Chen WT, Hu JH, Chen SC, Gu PW, Chien RN. Altering retinol binding protein 4 levels in hepatitis C: Inflammation and steatosis matter. Virulence 2020;11:1501-11. [PMID: 33135589 DOI: 10.1080/21505594.2020.1838742] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
93 Huang SC, Cheng PN, Liu CH, Yang HC, Su TH, Tseng TC, Chen PJ, Kao JH, Liu CJ. Serum cytokine/chemokine profiles predict hepatitis B reactivation in HBV/HCV co-infected subjects receiving direct-acting antiviral agents. J Formos Med Assoc 2021:S0929-6646(21)00424-1. [PMID: 34538552 DOI: 10.1016/j.jfma.2021.09.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
94 Benade M, Rosen S, Antoniak S, Chasela C, Stopolianska Y, Barnard T, Gandhi M, Ivanchuk I, Tretiakov V, Dible J, Minior T, Chew K, van der Horst C, Tsenilova Z, Sanne I, for EQUIP Health. Impact of direct-acting antiviral treatment of hepatitis C on the quality of life of adults in Ukraine.. [DOI: 10.1101/2021.09.08.21263288] [Reference Citation Analysis]
95 Zeng DY, Li JM, Lin S, Dong X, You J, Xing QQ, Ren YD, Chen WM, Cai YY, Fang K, Hong MZ, Zhu Y, Pan JS. Global burden of acute viral hepatitis and its association with socioeconomic development status, 1990-2019. J Hepatol 2021;75:547-56. [PMID: 33961940 DOI: 10.1016/j.jhep.2021.04.035] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 11.5] [Reference Citation Analysis]
96 Huang X, Glessner JT, Huang J, Zhou D, March ME, Wang H, Xia Q, Hakonarson H, Li J. Discovery of Novel Host Molecular Factors Underlying HBV/HCV Infection. Front Cell Dev Biol 2021;9:690882. [PMID: 34458256 DOI: 10.3389/fcell.2021.690882] [Reference Citation Analysis]
97 Giovannoni F, Li Z, Remes-Lenicov F, Dávola ME, Elizalde M, Paletta A, Ashkar AA, Mossman KL, Dugour AV, Figueroa JM, Barquero AA, Ceballos A, Garcia CC, Quintana FJ. AHR signaling is induced by infection with coronaviruses. Nat Commun 2021;12:5148. [PMID: 34446714 DOI: 10.1038/s41467-021-25412-x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
98 Chen Y, Lin J, Zhao Y, Ma X, Yi H. Toll-like receptor 3 (TLR3) regulation mechanisms and roles in antiviral innate immune responses. J Zhejiang Univ Sci B 2021;22:609-32. [PMID: 34414698 DOI: 10.1631/jzus.B2000808] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
99 Tsui JI, Barry MP, Austin EJ, Sweek EW, Tung E, Hansen RN, Ninburg M, Scott JD, Glick SN, Williams EC. 'Treat my whole person, not just my condition': qualitative explorations of hepatitis C care delivery preferences among people who inject drugs. Addict Sci Clin Pract 2021;16:52. [PMID: 34384494 DOI: 10.1186/s13722-021-00260-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
100 Chang ML, Hu JH, Pao LH, Lin MS, Kuo CJ, Chen SC, Fan CM, Chang MY, Chien RN. Critical role of triglycerides for adiponectin levels in hepatitis C: a joint study of human and HCV core transgenic mice. BMC Immunol 2021;22:54. [PMID: 34380427 DOI: 10.1186/s12865-021-00445-5] [Reference Citation Analysis]
101 Maruyama H, Shiina S. Collaterals in portal hypertension: anatomy and clinical relevance. Quant Imaging Med Surg 2021;11:3867-81. [PMID: 34341755 DOI: 10.21037/qims-20-1328] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
102 Frosi A. Extrahepatic Manifestations of Hepatitis C Infection. Advances in Hepatology 2021. [DOI: 10.5772/intechopen.95995] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
103 Yang X, Tang Y, Xu D, Zhang G, Xu P, Tang H, Pang L. Efficacy and safety of ledipasvir/sofosbuvir for hepatitis C among drug users: a systematic review and meta-analysis. Virol J 2021;18:156. [PMID: 34315488 DOI: 10.1186/s12985-021-01625-w] [Reference Citation Analysis]
104 Lin HH, Hsu SJ, Lu SN, Chuang WL, Hsu CW, Chien RN, Yang SS, Su WW, Wu JC, Lee TH, Peng CY, Tseng KC, Qin A, Huang YW, Chen PJ. Ropeginterferon alfa-2b in patients with genotype 1 chronic hepatitis C: Pharmacokinetics, safety, and preliminary efficacy. JGH Open 2021;5:929-40. [PMID: 34386602 DOI: 10.1002/jgh3.12613] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
105 Zhang W, Aryan M, Qian S, Cabrera R, Liu X. A Focused Review on Recent Advances in the Diagnosis and Treatment of Viral Hepatitis. Gastroenterology Res 2021;14:139-56. [PMID: 34267829 DOI: 10.14740/gr1405] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
106 Rezende AGDS, Lopes EP, Batista AD, Filgueira NA, Costa WER, Felix PMDS, Markman B. Treatment of Hepatitis C with Direct-Acting Antivirals does not Induce Significant Arrhythmias. International Journal of Cardiovascular Sciences 2021. [DOI: 10.36660/ijcs.20200220] [Reference Citation Analysis]
107 Fu Z, Menéndez‐arias L, Liu X, Zhan P. Advances in Natural Products‐Based Antiviral Agents. Chemistry of Biologically Potent Natural Products and Synthetic Compounds 2021. [DOI: 10.1002/9781119640929.ch2] [Reference Citation Analysis]
108 Fu Z, Dong C, Ge Z, Wang C, Zhang Y, Shen C, Li J, Zhu C, Wang Y, Huang P, Yue M. High SVR12 With 8-Week Course of Direct-Acting Antivirals in Adolescents and Children With Chronic Hepatitis C: A Comprehensive Analysis. Front Med (Lausanne) 2021;8:608760. [PMID: 34169081 DOI: 10.3389/fmed.2021.608760] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
109 Pramod S, Kheetan M, Ogu I, Alsanani A, Khitan Z. Viral Nephropathies, Adding SARS-CoV-2 to the List. Int J Nephrol Renovasc Dis 2021;14:157-64. [PMID: 34113150 DOI: 10.2147/IJNRD.S303080] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
110 Solitano V, Plaz Torres MC, Pugliese N, Aghemo A. Management and Treatment of Hepatitis C: Are There Still Unsolved Problems and Unique Populations? Viruses 2021;13:1048. [PMID: 34205966 DOI: 10.3390/v13061048] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
111 Sarrazin C. Treatment failure with DAA therapy: Importance of resistance. J Hepatol 2021;74:1472-82. [PMID: 33716089 DOI: 10.1016/j.jhep.2021.03.004] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 14.5] [Reference Citation Analysis]
112 Estefan S, Brandão-Melo CE, Dos Santos Silva CM, Gomes DCK, Cardoso P, Costa MHS. Metabolic Evaluation in Patients With Hepatitis C Treated With Direct Antiviral Agents. Front Med (Lausanne) 2021;8:631600. [PMID: 34136497 DOI: 10.3389/fmed.2021.631600] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
113 Recio Comí G, Molina Clavero C, Calabuig Ballester S, Benavent Bofill C, Picó-plana E, Martín Grau C, Gutiérrez Fornés C, Sans Mateu MT. Falso negativo en serología de VHC debido a interferencia por crioglobulinas. Advances in Laboratory Medicine / Avances en Medicina de Laboratorio 2021;2:301-304. [DOI: 10.1515/almed-2021-0004] [Reference Citation Analysis]
114 Recio Comí G, Molina Clavero C, Calabuig Ballester S, Benavent Bofill C, Picó-plana E, Martín Grau C, Gutiérrez Fornés C, Sans Mateu MT. False-seronegative HCV infection motivated by interference with cryoglobulins. Advances in Laboratory Medicine / Avances en Medicina de Laboratorio 2021;2:297-300. [DOI: 10.1515/almed-2020-0086] [Reference Citation Analysis]
115 Tabata K, Prasad V, Paul D, Lee J, Pham M, Twu W, Neufeldt CJ, Cortese M, Cerikan B, Si Tran C, Lüchtenborg C, V’kovski P, Hörmann K, Müller AC, Zitzmann C, Haselmann U, Beneke J, Kaderali L, Erfle H, Thiel V, Lohmann V, Superti-furga G, Brügger B, Bartenschlager R. Convergent use of phosphatidic acid for Hepatitis C virus and SARS-CoV-2 replication organelle formation.. [DOI: 10.1101/2021.05.10.443480] [Reference Citation Analysis]
116 Fagan O, Armstrong P, Merwe KVD, Crosnoi D, Steele C, Sopena-Falco J, Parihar V. Viral hepatitis: A brief introduction, review of management, advances and challenges. World J Meta-Anal 2021; 9(2): 139-152 [DOI: 10.13105/wjma.v9.i2.139] [Reference Citation Analysis]
117 Safaev K, Parpieva N, Liverko I, Yuldashev S, Dumchev K, Gadoev J, Korotych O, Harries AD. Trends, Characteristics and Treatment Outcomes of Patients with Drug-Resistant Tuberculosis in Uzbekistan: 2013-2018. Int J Environ Res Public Health 2021;18:4663. [PMID: 33925705 DOI: 10.3390/ijerph18094663] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
118 Sidorkiewicz M. Hepatitis C Virus Uses Host Lipids to Its Own Advantage. Metabolites 2021;11:273. [PMID: 33925362 DOI: 10.3390/metabo11050273] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
119 Su X, Zhao X, Deng JL, Li SN, Du X, Dong JZ, Ma CS. Antiviral treatment for hepatitis C is associated with a reduced risk of atherosclerotic cardiovascular outcomes: A systematic review and meta-analysis. J Viral Hepat 2021;28:664-71. [PMID: 33452699 DOI: 10.1111/jvh.13469] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
120 Nishikawa H, Yoh K, Enomoto H, Nishimura T, Nishiguchi S, Iijima H. Combined grip strength and calf circumference as a useful prognostic system in patients with liver diseases: a large cohort study. Ann Transl Med 2021;9:624. [PMID: 33987322 DOI: 10.21037/atm-20-6901] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
121 Rogers ME, Balistreri WF. Cascade of care for children and adolescents with chronic hepatitis C. World J Gastroenterol 2021; 27(12): 1117-1131 [PMID: 33828389 DOI: 10.3748/wjg.v27.i12.1117] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
122 Fu Z, Cai W, Shao J, Xue H, Ge Z, Fan H, Dong C, Wang C, Zhang J, Shen C, Zhang Y, Huang P, Yue M. Genetic Variants in TNFSF4 and TNFSF8 Are Associated With the Risk of HCV Infection Among Chinese High-Risk Population. Front Genet 2021;12:630310. [PMID: 33841497 DOI: 10.3389/fgene.2021.630310] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
123 Chang ML, Chang SW, Chen SC, Chien RN, Hsu CL, Chang MY, Fann CSJ. Genetic Association of Hepatitis C-Related Mixed Cryoglobulinemia: A 10-Year Prospective Study of Asians Treated with Antivirals. Viruses 2021;13:464. [PMID: 33799903 DOI: 10.3390/v13030464] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
124 Onorato L, Pisaturo M, Starace M, Minichini C, Di Fraia A, Astorri R, Coppola N. Virological Factors Associated with Failure to the Latest Generation of Direct Acting Agents (DAA) and Re-Treatment Strategy: A Narrative Review. Viruses 2021;13:432. [PMID: 33800289 DOI: 10.3390/v13030432] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
125 Hofmann M, Tauber C, Hensel N, Thimme R. CD8+ T Cell Responses during HCV Infection and HCC. J Clin Med 2021;10:991. [PMID: 33801203 DOI: 10.3390/jcm10050991] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
126 Moradifard S, Sharifi Z, Arabkhazaeli A, Ghasemi F. Evaluating serum levels of miR-181a and miR-let7a in HCV infected Iranian patients compared with healthy individuals. Gene Reports 2021;22:101001. [DOI: 10.1016/j.genrep.2020.101001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
127 Whiteley D, Speakman E, Elliott L, Davidson K, Hamilton E, Jarvis H, Quinn M, Flowers P. Provider-related barriers and enablers to the provision of hepatitis C treatment by general practitioners in Scotland: A behaviour change analysis. J Viral Hepat 2021;28:528-37. [PMID: 33215781 DOI: 10.1111/jvh.13443] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
128 Oliveira AIN, Malta FM, Zitelli PMY, Salles APM, Gomes-Gouvea MS, Nastri ACS, Pinho JRR, Carrilho FJ, Oliveira CP, Mendes-Corrêa MC, Pessoa MG, Mazo DF. The role of PNPLA3 and TM6SF2 polymorphisms on liver fibrosis and metabolic abnormalities in Brazilian patients with chronic hepatitis C. BMC Gastroenterol 2021;21:81. [PMID: 33622266 DOI: 10.1186/s12876-021-01654-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
129 Wiegand J, Berg T. Hepatitis C-committing the world to an eradication of the infection. Hepatobiliary Surg Nutr 2021;10:96-9. [PMID: 33575293 DOI: 10.21037/hbsn.2020.03.26] [Reference Citation Analysis]
130 Balagopal A, Thio CL. When viruses collide: hepatitis B virus reactivation after hepatitis C treatment. J Clin Invest 2020;130:2823-6. [PMID: 32420916 DOI: 10.1172/JCI137477] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
131 Chang ML, Lin YS, Chang MY, Hsu CL, Chien RN, Fann CS. Accelerated cardiovascular risk after viral clearance in hepatitis C patients with the NAMPT-rs61330082 TT genotype: An 8-year prospective cohort study. Virulence 2021;12:270-80. [PMID: 33446046 DOI: 10.1080/21505594.2020.1870080] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
132 Wang CR, Tsai HW. Human hepatitis viruses-associated cutaneous and systemic vasculitis. World J Gastroenterol 2021; 27(1): 19-36 [PMID: 33505148 DOI: 10.3748/wjg.v27.i1.19] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 12] [Article Influence: 6.5] [Reference Citation Analysis]
133 Sepulveda-Crespo D, Resino S, Martinez I. Strategies Targeting the Innate Immune Response for the Treatment of Hepatitis C Virus-Associated Liver Fibrosis. Drugs 2021;81:419-43. [PMID: 33400242 DOI: 10.1007/s40265-020-01458-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
134 Thimme R. T cell immunity to hepatitis C virus: Lessons for a prophylactic vaccine. J Hepatol 2021;74:220-9. [PMID: 33002569 DOI: 10.1016/j.jhep.2020.09.022] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 13.5] [Reference Citation Analysis]
135 Enomoto H, Ueno Y, Hiasa Y, Nishikawa H, Hige S, Takikawa Y, Taniai M, Ishikawa T, Yasui K, Takaki A, Takaguchi K, Ido A, Kurosaki M, Kanto T, Nishiguchi S; Japan Etiology of Liver Cirrhosis Study Group in the 54th Annual Meeting of JSH. The transition in the etiologies of hepatocellular carcinoma-complicated liver cirrhosis in a nationwide survey of Japan. J Gastroenterol 2021;56:158-67. [PMID: 33219410 DOI: 10.1007/s00535-020-01748-x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 9.5] [Reference Citation Analysis]
136 Bove G, Mehnert A, Dao Thi VL. iPSCs for modeling hepatotropic pathogen infections. iPSCs for Studying Infectious Diseases 2021. [DOI: 10.1016/b978-0-12-823808-0.00013-4] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
137 Shmeleva EV, Colucci F. Maternal natural killer cells at the intersection between reproduction and mucosal immunity. Mucosal Immunol 2021;14:991-1005. [PMID: 33903735 DOI: 10.1038/s41385-020-00374-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
138 Khlaiphuengsin A, Chuaypen N, Sodsai P, Reantragoon R, Han WM, Avihingsanon A, Tangkijvanich P. Successful direct-acting antiviral therapy improves circulating mucosal-associated invariant T cells in patients with chronic HCV infection. PLoS One 2020;15:e0244112. [PMID: 33382729 DOI: 10.1371/journal.pone.0244112] [Reference Citation Analysis]
139 Messina V, Onorato L, Di Caprio G, Claar E, Iovinella V, Russo A, Rosato V, Salzillo A, Nevola R, Simeone F, Curcio F, Pisaturo M, Coppola N. Directly Acting Antiviral-Based Treatment for HCV-Infected Persons Who Inject Drugs: A Multicenter Real-Life Study. Life (Basel) 2020;11:17. [PMID: 33396802 DOI: 10.3390/life11010017] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
140 Liu Z, Shi O, Zhang T, Jin L, Chen X. Disease burden of viral hepatitis A, B, C and E: A systematic analysis. J Viral Hepat 2020;27:1284-96. [PMID: 32741034 DOI: 10.1111/jvh.13371] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
141 Castro Filho EC, Piedade J, Castro R, Luz PM, Fernandes F, Grinsztejn B, Veloso VG, Pereira GH, Perazzo H. Effectiveness of direct-acting agents for chronic hepatitis C treatment in South America: A systematic review and meta-analysis. J Viral Hepat 2020;27:1396-407. [PMID: 32706518 DOI: 10.1111/jvh.13364] [Reference Citation Analysis]
142 Magri MC, Manchiero C, Dantas BP, da Silva Nunes AK, Figueiredo GM, Barone AA, Tengan FM. Hepatitis E virus seroprevalence in patients with chronic hepatitis C at a university hospital in Brazil. Future Virology 2020;15:791-9. [DOI: 10.2217/fvl-2020-0042] [Reference Citation Analysis]
143 Xu B, Deng Y, Li X, Guo S, Gao Z, Xu W, Li Y, Zhang P, Zhang L, Huang J. Development and validation of a LC-MS/MS method for simultaneous determination of TQ-A3326 and its major metabolites in human plasma, urine and feces: application to pharmacokinetic assay. Xenobiotica 2020;50:1451-60. [PMID: 32520645 DOI: 10.1080/00498254.2020.1781292] [Reference Citation Analysis]
144 Zheng F, Li N, Xu Y, Zhou Y, Li YP. Adaptive mutations promote hepatitis C virus assembly by accelerating core translocation to the endoplasmic reticulum. J Biol Chem 2021;296:100018. [PMID: 33144326 DOI: 10.1074/jbc.RA120.016010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
145 Chang ML, Hu JH, Yen CH, Chen KH, Kuo CJ, Lin MS, Lee CH, Chen SC, Chien RN. Evolution of ferritin levels in hepatitis C patients treated with antivirals. Sci Rep. 2020;10:19744. [PMID: 33184464 DOI: 10.1038/s41598-020-76871-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
146 Charison JC, Schneider CE, Poliquin V. Intrauterine Blood Transfusion in an HCV and HIV Co-Infected Woman. Maternal-Fetal Medicine 2021;3:69-70. [DOI: 10.1097/fm9.0000000000000081] [Reference Citation Analysis]
147 Chang ML, Yang Z, Yang SS. Roles of Adipokines in Digestive Diseases: Markers of Inflammation, Metabolic Alteration and Disease Progression. Int J Mol Sci 2020;21:E8308. [PMID: 33167521 DOI: 10.3390/ijms21218308] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 8.0] [Reference Citation Analysis]
148 Akella A, Akella S. Applying Machine Learning to Evaluate for Fibrosis in Chronic Hepatitis C.. [DOI: 10.1101/2020.11.02.20224840] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
149 Tamori A, Uchida-Kobayashi S, Kozuka R, Motoyama H, Yoshida K, Odagiri N, Kotani K, Kawamura E, Fujii H, Hagihara A, Enomoto M, Kawada N. High dropout rate from aftercare program of antihepatitis C therapy for patients with history of injection drug use. JGH Open 2020;4:964-9. [PMID: 33102771 DOI: 10.1002/jgh3.12376] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
150 Vivaldini SM, Abraão Ribeiro R, Júnior GM, Tonini KC, Pereira GFM, de Araújo WN. A Real-life Study of the Positive Response to DAA-based Therapies for Hepatitis C in Brazil.. [DOI: 10.1101/2020.10.06.20207274] [Reference Citation Analysis]
151 de Lédinghen V, Lusivika-Nzinga C, Bronowicki JP, Zoulim F, Larrey D, Metivier S, Tran A, Marcellin P, Samuel D, Chazouillères O, Chevaliez S, Dorival C, Fontaine H, Pawlotsky JM, Carrat F, Pol S; AFEF/ANRS Study Group. Sofosbuvir-Daclatasvir is suboptimal in patients with genotype 2 chronic hepatitis C infection: real-life experience from the HEPATHER ANRS CO22 cohort. J Viral Hepat 2020;27:964-73. [PMID: 32436335 DOI: 10.1111/jvh.13321] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
152 Alzahrani N, Wu MJ, Shanmugam S, Yi M. Delayed by Design: Role of Suboptimal Signal Peptidase Processing of Viral Structural Protein Precursors in Flaviviridae Virus Assembly. Viruses 2020;12:E1090. [PMID: 32993149 DOI: 10.3390/v12101090] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
153 Mosa AI, AbouHaidar MG, Urbanowicz RA, Tavis JE, Ball JK, Feld JJ. Role of HVR1 sequence similarity in the cross-genotypic neutralization of HCV. Virol J 2020;17:140. [PMID: 32948191 DOI: 10.1186/s12985-020-01408-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
154 Qian X, Xu C, Wu B, Tang H, Zhao P, Qi Z. SNORD126 Promotes Hepatitis C Virus Infection by Upregulating Claudin-1 via Activation of PI3K-AKT Signaling Pathway. Front Microbiol 2020;11:565590. [PMID: 33042070 DOI: 10.3389/fmicb.2020.565590] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
155 Kemming J, Thimme R, Neumann-Haefelin C. Adaptive Immune Response against Hepatitis C Virus. Int J Mol Sci 2020;21:E5644. [PMID: 32781731 DOI: 10.3390/ijms21165644] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
156 Jing W, Liu J, Liu M. Global Trends and Regional Differences in Hepatitis C Virus Infection Prevalence and Implications for Prevention - Worldwide, 1990-2017. China CDC Wkly 2020;2:564-9. [PMID: 34594709 DOI: 10.46234/ccdcw2020.151] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
157 Marín-zuluaga JI, Díaz-ramírez GS. Tratamiento actual de la hepatitis C en Colombia. Hepatología 2020. [DOI: 10.52784/27112330.119] [Reference Citation Analysis]
158 Sepulveda-Crespo D, Resino S, Martinez I. Hepatitis C virus vaccine design: focus on the humoral immune response. J Biomed Sci 2020;27:78. [PMID: 32631318 DOI: 10.1186/s12929-020-00669-4] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
159 Takemura K, Takizawa E, Tamori A, Nakamae M, Kubota H, Uchida-Kobayashi S, Enomoto M, Kawada N, Hino M. Post-Treatment M2BPGi Level and the Rate of Autotaxin Reduction are Predictive of Hepatocellular Carcinoma Development after Antiviral Therapy in Patients with Chronic Hepatitis C. Int J Mol Sci 2020;21:E4517. [PMID: 32630450 DOI: 10.3390/ijms21124517] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
160 Sepulveda-Crespo D, Resino S, Martinez I. Innate Immune Response against Hepatitis C Virus: Targets for Vaccine Adjuvants. Vaccines (Basel) 2020;8:E313. [PMID: 32560440 DOI: 10.3390/vaccines8020313] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
161 Zhou QH, Wu FT, Pang LT, Zhang TB, Chen Z. Role of γδT cells in liver diseases and its relationship with intestinal microbiota. World J Gastroenterol 2020; 26(20): 2559-2569 [PMID: 32523311 DOI: 10.3748/wjg.v26.i20.2559] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
162 Alvaro-Meca A, Maté-Cano I, Ryan P, Briz V, Resino S. Epidemiological Trend of Sepsis in Patients with Hospital Admissions Related to Hepatitis C in Spain (2000-2015): A Nationwide Study. J Clin Med 2020;9:E1607. [PMID: 32466412 DOI: 10.3390/jcm9061607] [Reference Citation Analysis]
163 Piecha F, Gänßler JM, Ozga AK, Wehmeyer MH, Dietz J, Kluwe J, Laschtowitz A, von Felden J, Sterneck M, Jordan S, Pischke S, Lohse AW, Schulze Zur Wiesch J. Treatment and re-treatment results of HCV patients in the DAA era. PLoS One 2020;15:e0232773. [PMID: 32369527 DOI: 10.1371/journal.pone.0232773] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
164 Wendt S, Kühn A, Schneider A, Trawinski H, Lübbert C. Lebererkrankungen bei Reiserückkehrern. Gastroenterologe 2020;15:211-226. [DOI: 10.1007/s11377-020-00433-y] [Reference Citation Analysis]
165 Roingeard P, Beaumont E. Hepatitis C Vaccine: 10 Good Reasons for Continuing. Hepatology 2020;71:1845-50. [PMID: 32060946 DOI: 10.1002/hep.31182] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 8.0] [Reference Citation Analysis]
166 da Silva CB, Vieira DA, de Melo LF, Chagas ALS, Gomes AD, Faria Jr CLL, Teixeira R, de Magalhães Queiroz DM, Rocha GA, Soares MMS, Bezerra JMT, Silva LD. Interleukin-6-174G/C polymorphism is associated with a decreased risk of type 2 diabetes in patients with chronic hepatitis C virus. World J Hepatol 2020; 12(4): 137-148 [PMID: 32685106 DOI: 10.4254/wjh.v12.i4.137] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
167 Dengu F, Abbas SH, Ebeling G, Nasralla D. Normothermic Machine Perfusion (NMP) of the Liver as a Platform for Therapeutic Interventions during Ex-Vivo Liver Preservation: A Review. J Clin Med. 2020;9. [PMID: 32272760 DOI: 10.3390/jcm9041046] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 6.3] [Reference Citation Analysis]
168 Ferreira AR, Ramos B, Nunes A, Ribeiro D. Hepatitis C Virus: Evading the Intracellular Innate Immunity. J Clin Med 2020;9:E790. [PMID: 32183176 DOI: 10.3390/jcm9030790] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 4.7] [Reference Citation Analysis]
169 Shin EC, Han JW, Kang W, Kato T, Kim SJ, Zhong J, Kim S, Park SH, Sung PS, Watashi K, Park JY, Windisch MP, Oh JW, Wakita T, Han KH, Jang SK. The Beginning of Ending Hepatitis C Virus: A Summary of the 26th International Symposium on Hepatitis C Virus and Related Viruses. Viruses 2020;12:E302. [PMID: 32168867 DOI: 10.3390/v12030302] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
170 Masalova OV, Lesnova EI, Klimova RR, Momotyuk ED, Kozlov VV, Ivanova AM, Payushina OV, Butorina NN, Zakirova NF, Narovlyansky AN, Pronin AV, Ivanov AV, Kushch AA. Genetically Modified Mouse Mesenchymal Stem Cells Expressing Non-Structural Proteins of Hepatitis C Virus Induce Effective Immune Response. Vaccines (Basel). 2020;8. [PMID: 32024236 DOI: 10.3390/vaccines8010062] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
171 Zezai D, Chinnakali P, Dlodlo RA, Mugauri HD, Owiti P, Mutenherwa M, Mavunganidze G, Marowa LM, Mapako T. Safety of Blood Maintained in Zimbabwe: Low Transfusion Transmissible Infections among Blood Donors. JBM 2020;08:35-43. [DOI: 10.4236/jbm.2020.87004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
172 Ćupić M. Hepatitis C: Three decades of the path from discovery to the Nobel prize. Srpski medicinski časopis Lekarske komore 2020;1:115-121. [DOI: 10.5937/smclk2002115c] [Reference Citation Analysis]
173 Yang Y, Wu FP, Wang WJ, Shi JJ, Li YP, Zhang X, Dang SS. Real life efficacy and safety of direct-acting antiviral therapy for treatment of patients infected with hepatitis C virus genotypes 1, 2 and 3 in northwest China. World J Gastroenterol 2019; 25(44): 6551-6560 [PMID: 31802834 DOI: 10.3748/wjg.v25.i44.6551] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
174 Barik S. Molecular Interactions between Pathogens and the Circadian Clock. Int J Mol Sci 2019;20:E5824. [PMID: 31756974 DOI: 10.3390/ijms20235824] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]